Free Trial
NASDAQ:QTTB

Q32 Bio Q2 2025 Earnings Report

Q32 Bio logo
$1.79 -0.16 (-8.21%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$1.79 +0.00 (+0.06%)
As of 08/7/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio EPS Results

Actual EPS
-$0.78
Consensus EPS
-$1.14
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

Q32 Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Q32 Bio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Q32 Bio Earnings Headlines

Q32 Bio (QTTB) Q2 Loss Drops 45%
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
See More Q32 Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Q32 Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Q32 Bio and other key companies, straight to your email.

About Q32 Bio

Q32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

View Q32 Bio Profile

More Earnings Resources from MarketBeat